Note: Ingredients listed on restricted chemical lists
EC/CAS
72869-86-4
Name of the chemical
11,14-Dioxa-2,9-diazaheptadec-16-enoic Acid, 4,4,6,16-tetramethyl-10,15-dioxo, 2-[(2-methyl-1-oxo-2-propenyl)oxy]ethyl ester (31)
Concentration
40-70%
General Information
Version
1,1 - Replaces version 1,0
Revision date
2025-08-26
Product name
DURASPLINT LC
1.2.1 Relevant identified uses
dental use
Emergency telephone
+49 6131 19240
Icons in SDS
Company Information
company name
DeltaMed GmbH
e-mail address of the competent person responsible for the Safety Data Sheet
info@deltamed.de
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H317, H411
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Hazardous Ingredients
urethane dimethacrylate (UDMA) trimethylolpropane formal acrylate (CTFA) Ethyl phenyl(2,4,6-trimethylbenzoyl)phosphinate
Signal word
Warning
Hazard statements
H317 May cause an allergic skin reaction. H411 Toxic to aquatic life with long lasting effects.
Precautionary statements
P261 Avoid breathing dust/vapours/spray. P273 Avoid release to the environment. P280 Wear protective gloves/protective clothing/eye protection. P302+P352 IF ON SKIN: Wash with plenty of water and soap. P333+P313 If skin irritation or rash occurs: Get medical advice/attention. P391 Collect spillage. P501 Dispose of contents/container in accordance with local regulation.
Special rules for supplemental label elements for certain mixtures
Restricted to professional users
2.3 Other hazards
The substances in the mixture do not meet the PBT/vPvB criteria according to REACH, annex XIII. Polymerization with heat evolution may occur in the presence of radical forming substances (e.g. peroxides), reducing substances, and/or heavy metal ions.
2.1 Classification of the substance or mixture
Regulation (EC) No 1272/2008 Skin Sens. 1; H317 Aquatic Chronic 2; H411 Full text of hazard statements: see SECTION 16.
